Horizant OKed as restless legs syndrome treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and Xenoport for treating restless legs syndrome, the agency said Thursday.
The FDA approved Horizant (gabapentin enacarbil) as a once-daily treatment for moderate-to-severe RLS.
“People with restless legs syndrome can experience considerable distress from their symptoms,” FDA Division of Neurology Products director Russell Katz said. “Horizant provides significant help in treating these symptoms.”
AstraZeneca’s vandetanib receives approval from FDA
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by AstraZeneca for treating a rare form of thyroid cancer, the agency said.
The FDA announced the approval of the daily pill vandetanib for late-stage medullary thyroid cancer in patients whose disease is growing and causing symptoms but who are ineligible for surgery.
Medullary thyroid cancer involves specific cells found in the thyroid gland and can occur spontaneously or be part of a genetic disease. There currently are no FDA-approved treatments for this cancer.
As Earth Day approaches, NCPA promotes Dispose My Meds program
ALEXANDRIA, Va. — In anticipation of Earth Day 2011 on April 22, the National Community Pharmacists Association is encouraging community pharmacists to demonstrate their role as a respected and knowledgeable resource on all aspects of medications, from dispensing to disposal, the association announced Thursday.
To assist pharmacists in conveying that message, NCPA is offering to its members, discounts, product displays, as well as communications and marketing materials and event ideas as part of its successful prescription disposal program for consumers at the website DisposeMyMeds.org.
“On Earth Day and every day, community pharmacies that voluntarily offer drug disposal services for their patients have an opportunity to build their businesses while building better relationships with patients as they discuss their medication needs,” stated Robert Greenwood, NCPA president. “Pharmacists place a premium on monitoring what prescription drugs are taken, how they interact with other drugs, how effective they are and what side effects they might cause as way to ensure patients are getting the maximum results,” Greenwood said. “The Dispose My Meds program is another avenue to allow pharmacists to apply their clinical patient care knowledge and to promote proper adherence to the patient’s prescription medication regimen.”
The NCPA Dispose My Meds program was launched in conjunction with the 40th anniversary of Earth Week in April 2010 via a partnership with NCPA and Sharps Compliance in order to address two pressing issues in drug diversion and environmental contamination. As part of the program, NCPA members receive nearly 20% in discounts with shipping included on the products from the Sharps TakeAway Environmental Return System, along with free customizable marketing materials and a listing on the companion consumer website, DisposeMyMeds.org.
To date, more than 1,200 pharmacies in 48 states are participating in the program and have collected some 25,000 pounds of unused or expired noncontrolled medications, NCPA stated.